In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs

Journal of Pharmaceutical Sciences

Volumn 105, Issue 8, 2016, Pages 2381-2385

  Bukara, Katarina ^a,b   Schueller, Laurent ^c   Rosier, Jan ^c   Daems, Tinne ^c   Verheyden, Loes ^c   Eelen, Siemon ^c   Martens, Johan A ^d   Van den Mooter, Guy ^e   Bugarski, Branko ^b   Kiekens, Filip ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Formac Pharmaceuticals NV   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

dissolution; fenofibrate; oral bioavailability; ordered mesoporous silica; poor solubility

Indexed keywords

DRUG CARRIER; FENOFIBRATE; ORDERED MESOPOROUS SILICA; SILICON DIOXIDE; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STORAGE; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; HUMIDITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROCAPSULE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DOG; DRUG RELEASE; ORAL DRUG ADMINISTRATION; POROSITY; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DRUG CARRIERS; DRUG LIBERATION; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; MALE; POROSITY; SILICON DIOXIDE; SOLUBILITY;

EID: 84979041804     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.05.019     Document Type: Article

References (17)

1. 1 Guay, D., Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacoter 33:10 (1993), 1083–1103.
2. 2 Genest, J.J., Nguyen, N.H., Theroux, P., Davignon, J., Cohn, J.S., Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters on hypertrigliceridemic patients with low levels of high density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol 35:1 (2000), 164–172.
3. 3 Ming-Thau, S., Ching-Min, Y., Sokoloski, T.D., Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm 103:2 (1994), 137–146.
4. 4 Yousaf, A.M., Kim, D.W., Oh, Y.K., Yong, C.S., Kim, Y.O., Choi, H.G., Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation. Int J Nanomed 10 (2015), 1819–1830.
5. 5 Hens, B., Brouwers, J., Corsseti, M., Augustins, P., Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential. Eur J Pharm Sci 77 (2015), 40–47.
6. 6 Chen, Y., Lu, Y., Chen, J., et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrat by using liposomes containing a bile salt. Int J Pharm 376 (2009), 153–160.
7. 7 Fei, Y., Kostewicz, E.S., Sheu, M.T., Dressman, J.B., Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasting humans using an in vitro-in silico-in vivo approach. Eur J Pharm Sci 85 (2013), 1274–1284.
8. 8 Xu, W., Riikonen, J., Lehto, V.P., Mesoporous systems for poorly soluble drugs. Int J Pharm 453 (2013), 181–197.
9. 9 Mellaerts, R., Mols, R., Jammaer, J.A.G., et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered porous material. Eur J Pharm Biopharm 69 (2008), 223–230.
10. 10 Vialpando, M., Backhujis, F., Martens, J.A., Mooter, G.V., Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen and ibuprofen. Eur J Pharm Biopharm 81 (2012), 190–198.
11. 11 Van Speybroeck, M., Bariallaro, V., Do Thi, T., et al. Ordered mesoporous silica material SBA-15: a broad spectrum formulation platform for poorly soluble drugs. J Pharm Sci 98 (2009), 2648–2658.
12. 12 Mellaerts, R., Aerts, C.A., Van Humbeeck, J., Augustijns, P., Van den Mooter, G., Martens, J., Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem Commun 13 (2007), 1375–1377.
13. 13 Kiekens, F., Eelen, S., Verheyden, L., Daems, T., Martens, J., Van den Mooter, G., Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J Pharm Sci 101 (2011), 1136–1144.
14. 14 Dressman, J.B., Herbert, E., Wieber, A., Birk, G., Saal, C., Lubda, D., Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate. J Pharm Pharmacol 68:5 (2015), 1–12.
15. 15 Fei, Y., Herbert, E., Wieber, A., et al. Evaluation of the dissolution behaviour of novel fenofibrate silica formulations in preprandial biorelevant media. AAPS Poster M1189, AAPS Annual Meeting, San Antonio, Texas, 2013 Available at: http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/M1189.pdf. Accessed September 6, 2015.
16. 16 Van Speybroeck, M., Mellaerts, R., Mols, R., et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci 41 (2010), 623–630.
17. 17 Jammaer, J., Aerts, C.A., D'Haen, J., Won Seob, J., Martens, J., Convenient synthesis of ordered mesoporous silica at room temperature and quasi-neutral pH. J Mater Chem 19 (2009), 8290–8293.